Table 1 Baseline characteristics of IPF Patients
IPF Cohort (N= 4,716) | IPF Diagnostic Testing Subgroup (N= 2,518) | |||
|---|---|---|---|---|
Age (continuous, years) | ||||
Median, IQR | 77.5 | 72.0 - 82.0 | 77.0 | 71.0 - 81.0 |
Mean, SD | 76.8 | 5.9 | 76.3 | 5.8 |
Length of Health Plan Membership Prior to Cohort Entry (continuous, months) | ||||
Median, IQR | 34.3 | 21.5 - 58.6 | 34.7 | 21.6 - 59.1 |
Mean, SD | 47.6 | 37.9 | 48.1 | 38.4 |
N | % | N | % | |
Age (years) | ||||
65 – 74 | 1,683 | 35.7 | 981 | 39.0 |
75 – 84 | 2,633 | 55.8 | 1,366 | 54.2 |
85 +a | 400 | 8.5 | 171 | 6.8 |
Sex | ||||
Male | 2,374 | 50.3 | 1,319 | 52.4 |
Female | 2,342 | 49.7 | 1,199 | 47.6 |
Geographic Area | ||||
Northeast | 821 | 17.4 | 467 | 18.5 |
Midwest | 1,665 | 35.3 | 909 | 36.1 |
South | 1,776 | 37.7 | 911 | 36.2 |
West | 454 | 9.6 | 231 | 9.2 |
Race | ||||
White | 3,496 | 74.1 | 1,899 | 75.4 |
African American | 489 | 10.4 | 234 | 9.3 |
Hispanic/Latino | 302 | 6.4 | 170 | 6.8 |
Asian | 113 | 2.4 | 49 | 1.9 |
Other | 316 | 6.7 | 166 | 6.6 |
Cohort Entry Period | N | % | N | % |
2008 - 2009 | 970 | 20.6 | 525 | 20.8 |
2010 - 2011 | 1,401 | 29.7 | 731 | 29.0 |
2012 - 2014 | 2,345 | 49.7 | 1,262 | 50.1 |
Patients with at Least One | ||||
Diagnosis, Procedure, or | ||||
Dispensing for each of the | ||||
Following During the 12-Month Baseline Period: | ||||
Any Corticosteroid | 1,577 | 33.4 | 952 | 37.8 |
NAC | 40 | 0.8 | 24 | 1.0 |
Azathioprine | 27 | 0.6 | 15 | 0.6 |
Cyclophosphamide | 13 | 0.3 | 11 | 0.4 |
Open Lung Biopsies | 22 | 0.5 | 22 | 0.9 |
Oxygen Therapy | 1,093 | 23.2 | 654 | 26.0 |
GERD Therapy | 1,645 | 34.9 | 912 | 36.2 |
Anticoagulation/Antiplatelet Therapy | 1,346 | 28.5 | 781 | 31.0 |
Amiodarone | 172 | 3.6 | 107 | 4.2 |
Bleomycin | 2 | 0.0 | 2 | 0.1 |
Nitrofurantoin | 207 | 4.4 | 95 | 3.8 |
Methotrexate | 15 | 0.3 | 8 | 0.3 |
Gold Salts | 0 | 0.0 | 0 | 0.0 |
Epstein-Barr Virus | 9 | 0.2 | 7 | 0.3 |
Hepatitis C | 105 | 2.2 | 73 | 2.9 |
Bronchial Lavage | 150 | 3.2 | 139 | 5.5 |